Albany Internal Medicine — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$4,791	82
2024	Research	$604	2
2021	Research	$4,523	2
2020	Research	$9,265	2

Breakdown

Who paid Research payments · program years 2020–2025

Amgen Inc. $13,788 4 payments
Boehringer Ingelheim International GmbH $4,522 81 payments
Moderna TX, Inc. $604 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $269 1 payment

Studies the money was for Research payments · program years 2020–2025

Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) $13,788 4 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $4,791 82 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $604 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.